Pulse Biosciences (NASDAQ:PLSE) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Thursday, January 4th.
Separately, ValuEngine upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st.
Pulse Biosciences (NASDAQ:PLSE) opened at $24.22 on Thursday. Pulse Biosciences has a twelve month low of $5.82 and a twelve month high of $39.50. The stock has a market cap of $395.79 and a PE ratio of -17.30.
Pulse Biosciences (NASDAQ:PLSE) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.52) EPS for the quarter.
In other news, Director Maky Zanganeh purchased 4,000 shares of the stock in a transaction that occurred on Tuesday, December 12th. The stock was bought at an average cost of $23.07 per share, for a total transaction of $92,280.00. Following the acquisition, the director now directly owns 332,500 shares of the company’s stock, valued at approximately $7,670,775. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Robert W. Duggan purchased 22,901 shares of the stock in a transaction that occurred on Thursday, October 19th. The shares were purchased at an average price of $22.79 per share, with a total value of $521,913.79. Following the completion of the acquisition, the insider now directly owns 5,820,513 shares in the company, valued at $132,649,491.27. The disclosure for this purchase can be found here. Insiders own 6.70% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Nationwide Fund Advisors purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth about $177,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth about $250,000. Wells Fargo & Company MN grew its position in shares of Pulse Biosciences by 13.8% in the 3rd quarter. Wells Fargo & Company MN now owns 61,398 shares of the company’s stock worth $1,143,000 after buying an additional 7,465 shares during the period. California Public Employees Retirement System purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth about $297,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of Pulse Biosciences in the 2nd quarter worth about $310,000. Institutional investors and hedge funds own 9.30% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Pulse Biosciences (PLSE) Downgraded to “Sell” at BidaskClub” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/pulse-biosciences-plse-lowered-to-sell-at-bidaskclub.html.
About Pulse Biosciences
Pulse Biosciences, Inc, formerly Electroblate, Inc, is a development-stage medical device company using a platform technology called Nano-Pulse Electro-Signaling (NPES). NPES is a local and drug-free technology that utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways in tissue.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.